Acro Biomedical Co., Ltd.
ACBM
$0.03
$0.000.00%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 409.49% | 461.20% | 305.26% | 220.48% | -96.62% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 409.49% | 461.20% | 305.26% | 220.48% | -97.45% |
| Operating Income | -409.49% | -461.20% | -305.26% | -220.48% | 97.45% |
| Income Before Tax | -200.21% | -226.15% | -139.24% | -210.04% | 97.13% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -200.21% | -226.15% | -139.24% | -210.04% | 97.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -200.21% | -226.15% | -139.24% | -210.04% | 97.13% |
| EBIT | -409.49% | -461.20% | -305.26% | -220.48% | 97.45% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -166.67% | -187.50% | -125.00% | -200.00% | 96.69% |
| Normalized Basic EPS | -360.00% | -475.00% | -325.00% | -220.00% | 97.02% |
| EPS Diluted | -166.67% | -187.50% | -125.00% | -200.00% | 96.69% |
| Normalized Diluted EPS | -360.00% | -475.00% | -325.00% | -220.00% | 97.02% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |